IONS PE Ratio & Valuation, Is IONS Overvalued
Ionis Pharmaceuticals Inc (IONS) is currently in the "Fair zone" with a forward PS ratio of 8.76, slightly higher than its negative five-year average. Despite this, its current Price-to-Book ratio is significantly higher than its 3-year and 5-year averages, and its P/S ratio is 56.8% above the industry average. The article suggests this premium might be unsustainable given a revenue growth of -10.26%.
IONS Financials: Revenue Breakdown, Margins & Competitor Comparison
The article analyzes Ionis Pharmaceuticals Inc (IONS) financials, detailing its revenue breakdown, profitability margins, and comparison with competitors like MDGL and JAZZ. It highlights that "Ionis core" is the largest revenue contributor, and while the company boasts a high gross margin, its operating and net margins are negative. The analysis also benchmarks IONS's impressive gross margin against its peers in the Biotechnology & Medical Research industry.
Insider Sell Alert: Shannon Devers Sells Shares of Ionis Pharmaceuticals Inc (IONS)
Shannon Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals Inc, sold 6,193 shares of the company on April 2, 2026. This transaction follows a trend of insider selling at Ionis Pharmaceuticals, with 90 insider sells against 1 insider buy over the past year. The stock was trading at $74.05, placing its price-to-GF-Value ratio at 1.48, indicating it is significantly overvalued according to GuruFocus's intrinsic value estimate.
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 6,193 Shares
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers sold 6,193 shares for approximately $458,592, reducing her stake by 27.47% to 16,348 shares under a Rule 10b5-1 trading plan. The company recently missed quarterly EPS expectations but beat revenue estimates despite a 10.6% year-over-year revenue decline. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $92.84 for IONS.
J. Safra Sarasin Holding AG Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS
J. Safra Sarasin Holding AG recently acquired a new stake in Ionis Pharmaceuticals, buying 17,404 shares valued at approximately $1.38 million during the fourth quarter. This move comes as institutional investors now own 93.86% of the stock, while company insiders have been net sellers, offloading over a million shares in the past three months. Analysts currently rate Ionis Pharmaceuticals with a "Moderate Buy" consensus and an average price target of $92.84.
Assenagon Asset Management S.A. Cuts Stake in Ionis Pharmaceuticals, Inc. $IONS
Assenagon Asset Management S.A. significantly reduced its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 90.6% in Q4, now holding 29,316 shares valued at $2.32 million. Despite this, institutional investors collectively own 93.86% of the company, while corporate insiders have been selling shares. Analysts currently rate Ionis Pharmaceuticals as a "Moderate Buy" with an average price target of $92.84, even as the company reported a Q4 EPS miss.
The Bull Case For Ionis Pharmaceuticals (IONS) Could Change Following FDA Priority Review For Zilganersen
Ionis Pharmaceuticals' zilganersen has received FDA Priority Review for Alexander disease, highlighting the company's RNA-targeted platform and expanding its rare-disease franchise. This development could reshape Ionis's investment narrative, with analysts projecting significant revenue and earnings growth. Investors are advised to consider the potential for regulatory approvals, but also the concentration of catalyst events and execution risks.
Vanguard disaggregates holdings; reports 0 IONS shares (IONS)
Vanguard has filed an amended Schedule 13G/A, Amendment No. 14, reporting zero beneficial ownership of Ionis Pharmaceuticals (IONS) common stock. This change follows an internal realignment on January 12, 2026, where several Vanguard subsidiaries reorganized to report their holdings separately, as permitted by SEC Release No. 34-39538. Despite this disaggregation, the newly reporting entities will continue to pursue the same investment strategies.
Is It Time To Reassess Ionis Pharmaceuticals (IONS) After Its Strong One Year Share Price Run?
Ionis Pharmaceuticals (IONS) has seen significant share price appreciation over the past year, prompting a reassessment of its valuation. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by over 71%, trading at approximately $74.24 compared to an intrinsic value of $260.78, its Price to Sales (P/S) ratio of 13.00x currently indicates it is overvalued when compared to its industry and a tailored "Fair Ratio" of 5.17x. The article explores these conflicting valuations, along with different "Narratives" that consider various revenue growth assumptions and their impact on fair value, ranging from $62.78 to $93.90.
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS)
Analysts have issued bullish sentiments for two healthcare companies, COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS). LifeSci Capital reiterated a Buy rating for COMPASS Pathways with a $19.00 price target, while William Blair reiterated a Buy rating for Ionis Pharmaceuticals with a $72.70 price target. Both companies currently hold a "Strong Buy" consensus rating from analysts, indicating strong confidence in their future performance.
DAVENPORT & Co LLC Purchases 155,334 Shares of Ionis Pharmaceuticals, Inc. $IONS
DAVENPORT & Co LLC significantly increased its stake in Ionis Pharmaceuticals (IONS) by 248.3% in the fourth quarter, now holding 217,897 shares valued at $17.24 million. This comes as the FDA granted priority review to Ionis's NDA for zilganersen and several analysts raised their price targets for the stock, contributing to a "Moderate Buy" consensus. Despite positive institutional investor activity and regulatory news, the company reported a quarterly EPS miss and a year-over-year revenue decline.
Ionis Cuts Trygolza Price Ahead Of Big New Indication
Ionis Pharmaceuticals has cut the price of its drug Trygolza ahead of a significant new indication, positioning it competitively below Arrowhead's rival drug. This strategic pricing move has positively impacted Ionis's stock market performance and comes as both companies prepare for potential market competition in the super high triglyceride (sHTG) indication.
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Ionis Pharmaceuticals has repriced its triglyceride-lowering drug Tryngolza to $40,000 annually, down from $595,000. This strategic move aims to position the drug competitively ahead of a potential FDA approval for severe hypertriglyceridemia (sHTG) by June 30, opening up a significantly larger market. Analysts view the pricing adjustment positively, noting it aligns with payer cycles and clinical outcomes, supporting a higher revenue outlook for Ionis.
Why Barclays Thinks Ionis Is Headed for a 45% Surge From $73 to $106
Barclays has raised its price target for Ionis Pharmaceuticals (IONS) to $106, implying a 45% upside, driven by the potential $4 billion peak sales opportunity for olezarsen in severe hypertriglyceridemia and strong early commercial uptake of Tryngolza. Achieving this target requires successful regulatory approval for olezarsen, continued sales momentum, and careful management of operating losses to reach cash flow breakeven by 2028. The firm highlights the near-term PDUFA date for olezarsen and a robust pipeline as key drivers for the stock's future performance.
Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market
Ionis Pharmaceuticals has cut the annual list price of its triglyceride-lowering drug, Tryngolza, to $40,000 from $595,000, signaling a strategic move ahead of a potential FDA label expansion into severe hypertriglyceridemia (sHTG). This repricing positions the drug more competitively for a larger market opportunity, with an FDA decision expected by June 30. Analysts view the pricing revision positively, anticipating significant revenue upside and potential blockbuster status for Tryngolza if approved for sHTG.
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright
HC Wainwright has increased its price target for Ionis Pharmaceuticals (NASDAQ:IONS) to $120.00 from $110.00, maintaining a "buy" rating, indicating a potential 65% upside. This comes despite the company reporting mixed quarterly results with revenue beating expectations but EPS missing, and a year-over-year revenue decrease. The report also highlights significant insider selling, which could be a concern for investors.
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
Ionis Pharmaceuticals' new drug application for zilganersen, a treatment for Alexander disease (AxD), has been granted Priority Review by the FDA, with a target action date of September 22, 2026. This designation recognizes the drug's potential to significantly improve treatment for the rare, often fatal neurological disorder, accelerating its review to six months. If approved, zilganersen would be Ionis' third wholly-owned approved drug and its first entry into the neurology market, based on positive Phase III trial data.
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
The FDA has granted priority review to Ionis Pharmaceuticals' New Drug Application (NDA) for zilganersen, a treatment for Alexander disease (AxD). This decision accelerates the review process to six months, with a target action date of September 22, 2026. Zilganersen, if approved, would be Ionis' third wholly-owned approved drug and mark its entry into the neurology space.
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider sold 5,812 shares of common stock for $412,477.64 on March 19th, reducing his stake by 8.34%. This sale follows two earlier disposals in January. The company recently reported revenue that beat expectations but missed EPS estimates, receiving a "Moderate Buy" consensus from analysts with an average price target of $89.00.
Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA).
Ionis Pharmaceuticals, Inc. announced that its New Drug Application (NDA) for Zilganersen, a treatment for Alexander disease (AxD), has received Priority Review designation from the FDA. This designation is expected to shorten the drug's review period, offering expedited hope for patients with this rare neurological condition. The article emphasizes this development as a significant step forward in treating Alexander disease.
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
Ionis Pharmaceuticals has announced that the FDA has accepted its New Drug Application for zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), for Priority Review. This designation emphasizes the urgent need for treatment for AxD, a rare and fatal neurological condition with no approved disease-modifying therapies. The FDA has set a PDUFA target action date of September 22, 2026, and if approved, zilganersen would be the first and only treatment for AxD, marking a significant milestone for Ionis in neurology.
Affiliate files Form 144 to sell shares — IONS (NASDAQ: IONS)
An affiliate of Ionis Pharmaceuticals (IONS) has filed a Form 144 to sell common stock, indicating proposed sales linked to performance stock units from January 15, 2026, and a reported sale on March 19, 2026. The filing names Stifel Nicolaus & Company as the broker and details the sale of 6,179 shares. This is a routine notice for the intended resale of restricted securities, signaling potential resale supply without specifying immediate market impact.
Hudson Bay Capital Management LP Decreases Stock Position in Ionis Pharmaceuticals, Inc. $IONS
Hudson Bay Capital Management LP significantly reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 31.3% in the third quarter, now holding 515,000 shares valued at approximately $33.7 million. This comes amidst heavy insider selling, with the CEO and an EVP offloading shares totaling over $13 million, and operational results showing mixed performance with a revenue beat but an EPS miss. Despite insider sales, analysts maintain a "Moderate Buy" rating with an average target price of $89.00.
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Groupama Asset Managment
Groupama Asset Management reduced its stake in Ionis Pharmaceuticals ($IONS) by 8.5% in Q3, now owning 1,061,777 shares valued at $69.46 million. Insider selling by executives Patrick O'Neil and Kyle Jenne amounted to 1,030,070 shares worth approximately $80.08 million over the last three months. Ionis reported an EPS miss but beat revenue estimates, while analysts maintain a "Moderate Buy" rating with an average target price of $89.00.
Did Ionis Pharmaceuticals' (IONS) Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative?
Ionis Pharmaceuticals has announced a board refresh, with long-serving directors retiring and former director Peter N. Reikes rejoining. This move is expected to bring renewed regulatory and capital-markets expertise as the company prepares for potential product launches and critical clinical milestones. While the immediate investment narrative still centers on the June 30, 2026 PDUFA decision for olezarsen, Reikes's experience could aid future financing and regulatory engagement, addressing concerns about pricing pressure and commercialization.
Insider Sell: Elizabeth Hougen Sells 225,220 Shares of Ionis Pha
Elizabeth Hougen, Executive Vice President, Finance & Chief Financial Officer of Ionis Pharmaceuticals Inc (IONS), sold 225,220 shares on March 17, 2026. This transaction reduces her total holdings to 82,660 shares, contributing to a pattern of 87 insider sells versus 1 insider buy over the past year. The stock, trading at $72.43, is considered significantly overvalued with a price-to-GF-Value ratio of 1.44 against a GF Value of $50.26.
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $744,692.12 in Stock
Ionis Pharmaceuticals' EVP Elizabeth Hougen sold 10,172 shares of the company's stock for over $744,000, reducing her position by almost 11%. The transaction occurred on March 17th, with the stock trading below its 50-day moving average. Despite an EPS miss, analysts maintain a "Moderate Buy" rating with an average price target of $89.
Ionis Pharmaceuticals (NASDAQ: IONS) CFO sells 225,220 shares after option exercises
Ionis Pharmaceuticals' EVP, Finance & CFO Elizabeth L. Hougen exercised stock options to acquire 174,999 shares and subsequently sold a total of 225,220 shares in open-market transactions. These sales, conducted on March 16 and March 17, 2026, were made pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Ms. Hougen directly owns 82,660 shares of Ionis common stock.
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target
Ionis Pharmaceuticals (NASDAQ:IONS) entered 2026 with a strong commercial and pipeline outlook, leading Leerink to raise its price target to $104 from $102. The company reported significant revenue growth in 2025, buoyed by the launch of TRYNGOLZA and a payment from Ono Pharmaceutical, and projected strong revenue for 2026. Key catalysts for 2026 include a PDUFA date for TRYNGOLZA, and Phase 3 readouts for CARDIO-TTRansform and pelacarsen.
BlueCrest Capital Management Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS
BlueCrest Capital Management Ltd has made a new investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), purchasing 23,370 shares valued at approximately $1.53 million in Q3. This investment contributes to institutional investors owning around 93.86% of the company, despite recent insider selling by executives. Ionis Pharmaceuticals reported a Q3 EPS miss but exceeded revenue expectations, with analysts maintaining a "Moderate Buy" consensus and an average price target of $89.
Did Ionis Pharmaceuticals' (IONS) Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative?
Ionis Pharmaceuticals recently announced a board refresh, with long-serving directors retiring and former director Peter N. Reikes rejoining, bringing renewed regulatory and capital-markets expertise. This change comes as Ionis prepares for multiple potential launches and late-stage clinical milestones, including the PDUFA decision for olezarsen in severe hypertriglyceridemia by June 30, 2026. While Reikes's experience may assist with future financing and regulatory engagement, the primary investment narrative still hinges on execution and pricing pressure, especially with the upcoming olezarsen decision and Ionis's projected revenue and earnings by 2028.
Alpine Global Management LLC Acquires 30,463 Shares of Ionis Pharmaceuticals, Inc. $IONS
Alpine Global Management LLC significantly increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 119.8% in the third quarter, purchasing an additional 30,463 shares to bring its total holdings to 55,900 shares valued at $3,657,000. Other institutional investors also adjusted their positions in the company, while company executives have recently sold a substantial number of shares. Analysts have largely maintained a "Moderate Buy" consensus rating for Ionis Pharmaceuticals with an average price target of $89.00.
Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS
Bamco Inc. NY has made a new investment of $1.64 million in Ionis Pharmaceuticals, Inc. by acquiring 25,000 shares of the biotech company's stock during the third quarter. This investment signals Bamco's confidence in Ionis Pharmaceuticals' pipeline and future growth potential in RNA-targeted therapies. The acquisition was detailed in Bamco Inc. NY's recent 13F filing with the SEC.
Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS
Bamco Inc. NY has initiated a new $1.64 million investment in Ionis Pharmaceuticals (NASDAQ:IONS), acquiring 25,000 shares in Q3, while other institutional investors also increased their stakes. Despite these institutional investments, the article highlights significant insider selling, with the CEO and EVP disposing of shares totaling over $4 million, and over $63 million in insider sales in the last quarter. Ionis Pharmaceuticals faces mixed fundamentals with an EPS miss but a revenue beat, yet analysts maintain a "Moderate Buy" rating with an average target price of $89.
IONS (IONS) Form 144 notices proposed resale of 225,200 shares
Ionis Pharmaceuticals (IONS) has filed a Form 144, indicating a proposed resale of 225,200 shares of common stock stemming from an option exercise. Stifel Nicolaus & Company Inc is identified as the broker for this transaction. The filing also notes previous dispositions by Elizabeth Hougen on January 30, 2026, and January 16, 2026, for 6,988 and 12,922 shares, respectively.
Algert Global LLC Grows Position in Ionis Pharmaceuticals, Inc. $IONS
Algert Global LLC significantly increased its stake in Ionis Pharmaceuticals ($IONS) by 562.3% in Q3, now holding 252,281 shares valued at $16.5 million. This comes despite company insiders being net sellers, disposing of 804,850 shares worth $63.8 million in the past three months. Analysts maintain a "Moderate Buy" rating with an $89 target price, while the stock currently trades around $71, with a 12-month range between $23.95 and $86.74.
BlueCrest Capital Management Ltd Takes Position in Ionis Pharmaceuticals, Inc. $IONS
BlueCrest Capital Management Ltd acquired a new stake in Ionis Pharmaceuticals (NASDAQ:IONS) during Q3, purchasing 23,370 shares valued at approximately $1.53 million. Despite significant insider selling over the past 90 days, institutional investors now own 93.86% of the stock. Ionis Pharmaceuticals reported an earnings miss but had higher-than-expected revenue and holds a consensus "Moderate Buy" rating with an average target price of $89.
Cinctive Capital Management LP Invests $11.37 Million in Ionis Pharmaceuticals, Inc. $IONS
Cinctive Capital Management LP recently invested $11.37 million in Ionis Pharmaceuticals (NASDAQ: IONS) by purchasing 173,819 shares. This new stake represents 0.11% of the company, even as company insiders have been significant sellers, reducing their collective ownership to approximately 2.6%. Analysts generally rate Ionis as a "Moderate Buy" with an average price target of $89.00.
Boone Capital Management LLC Takes $27.34 Million Position in Ionis Pharmaceuticals, Inc. $IONS
Boone Capital Management LLC has acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) valued at $27.34 million, making it the firm's third-largest holding. Several other major hedge funds also significantly increased their stakes in Ionis, contributing to 93.86% institutional ownership of the company. Despite positive analyst sentiment with a "Moderate Buy" consensus and an $89 price target, Ionis missed EPS estimates in its latest quarterly earnings, and insiders have sold over $63 million worth of shares in the past 90 days.
IONS SEC Filings - Ionis Pharmaceuticals 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Ionis Pharmaceuticals (IONS) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It leverages AI-powered summaries to help investors interpret complex documents, covering clinical milestones, regulatory events, and financing transactions. Recent filings highlight positive Phase 3 results for olezarsen, FDA approval of DAWNZERA for hereditary angioedema, and various insider trading activities.
Connor Clark & Lunn Investment Management Ltd. Raises Stake in Ionis Pharmaceuticals, Inc. $IONS
Connor Clark & Lunn Investment Management Ltd. significantly increased its stake in Ionis Pharmaceuticals, Inc. during the third quarter, raising its holdings by 230.4% to own 878,155 shares valued at approximately $57.45 million. Despite this institutional confidence, company insiders have been net sellers, divesting over 800,000 shares recently. Ionis Pharmaceuticals holds a "Moderate Buy" consensus rating from analysts with an $89.00 price target, even after missing recent EPS estimates but exceeding revenue expectations.
Atika Capital Management LLC Invests $1.41 Million in Ionis Pharmaceuticals, Inc. $IONS
Atika Capital Management LLC has invested $1.41 million in Ionis Pharmaceuticals, acquiring 21,500 shares in the third quarter. Ionis Pharmaceuticals reported a quarterly EPS of ($1.41), missing estimates, but revenue of $203.33 million which beat consensus. Despite insider selling, institutional investors hold a significant portion of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $89.00.
Ionis (NASDAQ: IONS) EVP sells 37,277 shares under 10b5-1 plan
Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold a total of 37,277 shares in open-market transactions on March 10, 2026. The sales, conducted under a Rule 10b5-1 trading plan adopted on December 8, 2025, occurred at weighted average prices of $75.502 and $76.30 per share. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $9,525,584.00 in Stock
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia sold 126,670 shares of the company's stock for $9,525,584.00, reducing his stake by 34.3%. The company recently reported Q4 EPS of ($1.41), missing estimates, though revenue of $203.33 million beat expectations. Shares are currently trading around $74.79 and analysts generally rate the stock as a "Moderate Buy" with a consensus target price of $89.00.
Ionis Pharmaceuticals Presents at Barclays Healthcare Conference
Ionis Pharmaceuticals presented at the Barclays 28th Annual Global Healthcare Conference, with CEO Brett Monia highlighting 2026 as a "transformational year" due to a robust pipeline of catalysts. The company achieved significant momentum in 2025 with the successful launch of its first two independent medicines, including Tryngolza, which exceeded revenue expectations. Ionis, a genetic medicines company, is leveraging its RNA-targeting platform to address high unmet medical needs.
IONS (Nasdaq: IONS) insider notice: 37,277 shares from option exercises
Ionis Pharmaceuticals (Nasdaq: IONS) filed a Form 144, indicating proposed sales of 37,277 common shares resulting from option exercises, scheduled for March 10, 2026. The filing also disclosed a prior sale of 1,823 shares by Kyle Jenne on January 16, 2026, for $138,963. The proposed sales involve two lots of shares, acquired through option exercises in February 2024 and January 2025, to be sold for cash.
Capital World Investors Has $832.32 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS
Capital World Investors increased its stake in Ionis Pharmaceuticals by 1.5% to over 12.7 million shares, valued at $832.32 million, representing about 7.85% of the company. Despite this, insiders have been net sellers, disposing of over half a million shares worth approximately $48 million in the last 90 days. Ionis reported mixed financials, missing EPS expectations but beating revenue estimates, with analysts generally rating it a "Moderate Buy" with an average target price of $89.
Ionis EVP exercises options and sells shares | IONS SEC Filing - Form 4
Ionis Pharmaceuticals EVP and Chief Scientific Officer, Frank Bennett, reported exercising non-qualified stock options and subsequently selling shares on March 3, 2026. He exercised options for 16,463 shares at $32.60 and 48,626 shares at $60.89, then sold a total of 85,089 common shares in open-market trades at weighted average prices ranging from $79.099 to $80.762. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, leaving him with a direct ownership of 80,554 Ionis common shares.
Ionis (NASDAQ: IONS) HR executive sells 20,106 shares under 10b5-1 plan
Ionis Pharmaceuticals' EVP and Chief Human Resources Officer, Shannon L. Devers, sold 20,106 shares of common stock under a Rule 10b5-1 trading plan. The sales occurred in open-market transactions at weighted average prices ranging from $79.115 to $80.837 after exercising derivative securities. Following these transactions, Devers directly owns 22,541 shares of Ionis common stock.
Ionis pharma director Loscalzo sells $82k in shares
Joseph Loscalzo, a director at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 1,032 shares of common stock for approximately $82,832. Concurrently, he exercised options to acquire 1,032 shares at a lower price. This news comes as the company faces a target action date for its supplemental New Drug Application for olezarsen and prepares to present new data on DAWNZERA, with analysts responding by adjusting price targets.
